ETBD is a safe procedure with minimal complications, with subcutaneous emphysema being the most commonly reported adverse event, consistent with literature findings. A comprehensive analysis of AE, coupled with sales data, indicates a commendably low MDR rate of 0.0128 % for the Aera balloon while the Audion balloon had an MDR rate of 0.0164 %. These findings offer valuable insights on post-procedure expectations and engaging in informed consent discussions with patients, highlighting the overall safety of ETBD as an intervention.
Keyphrases
- end stage renal disease
- multidrug resistant
- electronic health record
- ejection fraction
- randomized controlled trial
- newly diagnosed
- minimally invasive
- systematic review
- big data
- chronic obstructive pulmonary disease
- peritoneal dialysis
- prognostic factors
- adverse drug
- emergency department
- idiopathic pulmonary fibrosis
- machine learning
- lung function
- data analysis